PHARMAESSENTIA CORPORATION |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 417 TWD | +2.58% |
|
+18.13% | +20.52% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 24,120 | 24,709 | 78,065 | 143,840 | 114,578 | 138,405 | - | - |
| Enterprise Value (EV) 1 | 22,809 | 21,664 | 75,148 | 133,629 | 94,995 | 119,467 | 119,200 | 122,340 |
| P/E ratio | -28.6 x | -11.7 x | -27.1 x | -98.6 x | -179 x | 82.6 x | 31.8 x | 22.8 x |
| Yield | - | - | - | - | - | 0.53% | 0.37% | - |
| Capitalization / Revenue | 78.9 x | 44.3 x | 119 x | 49.9 x | 22.4 x | 15.8 x | 10.7 x | 8.2 x |
| EV / Revenue | 74.6 x | 38.9 x | 114 x | 46.4 x | 18.6 x | 13.6 x | 9.22 x | 7.25 x |
| EV / EBITDA | -32 x | -14.1 x | -29 x | -74.2 x | -57.8 x | 53 x | 28.9 x | 23.5 x |
| EV / FCF | -21.4 x | -14.1 x | -29.7 x | -73.5 x | -49.8 x | -147 x | 75.3 x | - |
| FCF Yield | -4.67% | -7.09% | -3.37% | -1.36% | -2.01% | -0.68% | 1.33% | - |
| Price to Book | 11 x | 6.3 x | 19.1 x | 11.2 x | 4.79 x | 5.31 x | 4.71 x | 4.54 x |
| Nbr of stocks (in thousands) | 219,277 | 263,418 | 266,434 | 301,552 | 331,149 | 331,905 | - | - |
| Reference price 2 | 110.0 | 93.80 | 293.0 | 477.0 | 346.0 | 406.5 | 406.5 | 406.5 |
| Announcement Date | 2/26/20 | 3/3/21 | 3/2/22 | 3/1/23 | 2/27/24 | - | - | - |
1TWD in Million2TWD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 305.7 | 557.3 | 656.5 | 2,882 | 5,106 | 8,772 | 12,929 | 16,871 |
| EBITDA 1 | -711.8 | -1,541 | -2,595 | -1,800 | -1,645 | 2,255 | 4,125 | 5,212 |
| EBIT 1 | -849.2 | -1,716 | -2,822 | -2,028 | -1,913 | 1,200 | 3,971 | 5,293 |
| Operating Margin | -277.8% | -307.91% | -429.91% | -70.37% | -37.48% | 13.68% | 30.71% | 31.37% |
| Earnings before Tax (EBT) 1 | -842.1 | -1,948 | -2,811 | -1,842 | -986.9 | 1,885 | 5,225 | 6,774 |
| Net income 1 | -843 | -1,948 | -2,811 | -1,375 | -623.8 | 1,628 | 4,250 | 5,758 |
| Net margin | -275.77% | -349.59% | -428.17% | -47.7% | -12.22% | 18.55% | 32.87% | 34.13% |
| EPS 2 | -3.850 | -8.040 | -10.80 | -4.840 | -1.930 | 4.923 | 12.77 | 17.81 |
| Free Cash Flow 1 | -1,066 | -1,536 | -2,532 | -1,818 | -1,906 | -813 | 1,584 | - |
| FCF margin | -348.64% | -275.72% | -385.74% | -63.06% | -37.33% | -9.27% | 12.25% | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | 38.4% | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | 37.27% | - |
| Dividend per Share 2 | - | - | - | - | - | 2.150 | 1.513 | - |
| Announcement Date | 2/26/20 | 3/3/21 | 3/2/22 | 3/1/23 | 2/27/24 | - | - | - |
1TWD in Million2TWD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 380 | 251.7 | 977.7 | 810.8 | 841.7 | 887.6 | 1,265 | 1,306 | 1,647 | 1,653 | 2,045 | 2,362 | 2,824 |
| EBITDA | -891 | -490.7 | -270.5 | -510.5 | - | - | -348.9 | -585.6 | - | - | - | - | - |
| EBIT 1 | -951.9 | -557 | -326.6 | -564.9 | -579.7 | -725.5 | -404.8 | -645 | -132.1 | 17.58 | 157.5 | 407.5 | 789.5 |
| Operating Margin | -250.5% | -221.24% | -33.4% | -69.67% | -68.88% | -81.73% | -32.01% | -49.38% | -8.02% | 1.06% | 7.7% | 17.25% | 27.95% |
| Earnings before Tax (EBT) 1 | -886.8 | -540.9 | -274.7 | -408.8 | -617.5 | -760 | -203.1 | 190.9 | -214.7 | 334.6 | 276 | 526 | 915.5 |
| Net income 1 | -886.8 | -540.9 | -274.7 | -408.8 | -150.4 | -735.5 | -202.8 | 198.5 | 115.9 | 330.4 | 223 | 423.5 | 736 |
| Net margin | -233.37% | -214.84% | -28.1% | -50.42% | -17.87% | -82.86% | -16.03% | 15.2% | 7.04% | 19.98% | 10.9% | 17.93% | 26.06% |
| EPS 2 | -3.390 | -1.960 | -0.9800 | -1.440 | -0.4700 | -2.440 | -0.6200 | 0.6600 | 0.3800 | 0.9900 | 0.6700 | 1.265 | 2.200 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/2/22 | 5/16/22 | 8/12/22 | 11/14/22 | 3/1/23 | 5/11/23 | 8/10/23 | 11/9/23 | 2/27/24 | 5/13/24 | - | - | - |
1TWD in Million2TWD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 1,312 | 3,045 | 2,917 | 10,211 | 19,582 | 18,938 | 19,204 | 16,064 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -1,066 | -1,536 | -2,532 | -1,818 | -1,906 | -813 | 1,584 | - |
| ROE (net income / shareholders' equity) | -35.7% | -63.1% | -68.8% | -16.8% | -3.46% | 6.4% | 13% | 16.4% |
| ROA (Net income/ Total Assets) | -29.2% | -45.9% | -47.9% | -12.8% | -2.93% | 6.05% | 12.5% | 14.4% |
| Assets 1 | 2,882 | 4,245 | 5,865 | 10,765 | 21,301 | 26,901 | 33,914 | 40,109 |
| Book Value Per Share 2 | 10.00 | 14.90 | 15.30 | 42.70 | 72.30 | 76.60 | 86.40 | 89.50 |
| Cash Flow per Share 2 | -4.310 | -6.010 | -9.460 | - | -2.190 | -0.3000 | 6.530 | 14.10 |
| Capex 1 | 121 | 81.2 | 70.3 | 312 | 1,200 | 1,518 | 1,945 | - |
| Capex / Sales | 39.49% | 14.56% | 10.71% | 10.83% | 23.51% | 17.31% | 15.04% | - |
| Announcement Date | 2/26/20 | 3/3/21 | 3/2/22 | 3/1/23 | 2/27/24 | - | - | - |
1TWD in Million2TWD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
417
TWD
Average target price
428.2
TWD
Spread / Average Target
+2.70%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +20.52% | 4.18B | |
| +10.88% | 115B | |
| +12.34% | 106B | |
| -4.40% | 24.69B | |
| -2.33% | 21.97B | |
| -6.03% | 19.27B | |
| -12.85% | 17.56B | |
| -40.50% | 17.32B | |
| +6.38% | 14.03B | |
| +31.27% | 12.13B |
- Stock Market
- Equities
- 6446 Stock
- Financials PharmaEssentia Corporation
